Male Hypogonadism Market – By Treatment Type, By Route of Administration, By Application - Global Forecast 2025 – 2034

Male Hypogonadism Market Size

The global male hypogonadism market was estimated at USD 4 billion in 2024. The market is expected to grow from USD 4.2 billion in 2025 to USD 6.7 billion by 2034 at a CAGR of 5.2%. Male hypogonadism is a type medical condition where the body produces insufficient amount of testosterone or experiences impaired testicular function. Since the testes are responsible for making  testosterone and generate sperm, if fail to perform these functions appropriately, then leads to physical, sexual, and psychological symptoms.
 

The increasing prevalence of hypogonadism is a significant catalyst for the growth of the market. For instance, according to the Baltimore Aging Longitudinal study, low testosterone affects about 10% of men in their 50s, 20% in their 60s, and 30% in their 70s. Thus, these statistics highlight growing need for diagnosis and treatment options, and increased awareness to manage its impact on overall health and quality of life. Additionally, the global aging population is contributing to the increased prevalence of late-onset hypogonadism.
 

For instance, according to the World Health Organization (WHO), the number of individuals aged 80 years or older is expected to triple from 2020 to 2050, reaching 426 million. As older men are more likely to experience symptoms of low testosterone, this demographic change is escalating the demand for diagnostic testing and treatment solutions, significantly impacting healthcare needs related to the management of male hypogonadism.
 

Moreover, the growing awareness of men’s health and wellness has led to expanded initiatives which are focusing on male hypogonadism diagnosis and treatment. Thus, healthcare providers, government agencies and private organizations are focusing on spreading awareness, investing in education campaigns, and organizing preventive care programs to address this hormonal imbalances in men. For instance, the National Institutes of Health (NIH) and the American Urological Association (AUA) have introduced guidelines and awareness programs regarding early detection and management of testosterone deficiency.
 

Male Hypogonadism Market Trends

• Testosterone replacement therapy (TRT) has experienced significant innovations in recent years, which provides an effective, safer, and convenient treatment options for individuals suffering from male hypogonadism. Advancement in drug formulations, delivery methods, personalized treatment plans, and digital health, which is estimated to reach USD 981.5 billion by 2032, integration are transforming the management of testosterone deficiency.
   
• Pharmaceutical companies are developing new testosterone formulations and treatment that provides long-lasting effects and improved absorption. For instance, in March 2022 the FDA had approved the testosterone undecanoate by Antares  Pharma, Inc. for testosterone replacement therapy (TRT) for conditions associated with a deficiency or absence of endogenous testosterone, or hypogonadism in adult patients.
   
• Additionally, innovative delivery methods are expanding the convenience and effectiveness of TRT. Subcutaneous implants, a notable example for this is FDA approved Testopel which provide sustained testosterone release for up to six months, which minimizes the need for frequent administration.
   
• Similarly, intranasal testosterone such as Natesto, provides a quick and discreet option, bypassing skin absorption and reduces the risk of accidental transfer to others. These delivery advancements allow for greater flexibility in treatment.
   
• Further, the individualization of TRT is becoming more common, with microdosing strategies and tailored treatment plans improving patient adherence while minimizing side effects which includes erythrocytosis and cardiovascular risks, thus contributing to the market growth.
   

Male Hypogonadism Market Analysis

Based on treatment type, the market is bifurcated into testosterone replacement therapy and gonadotropin therapy. The market was estimated at USD 3.9 billion in 2023. The testosterone replacement therapy held revenue of USD 3.2 billion in 2024 and the segment is poised for significant growth at a CAGR of 5.3% during the forecast period.
 

• Testosterone plays a vital role in male sexual health, which influence libido, erectile function, and overall sexual satisfaction. Thus, testosterone replacement therapy (TRT) helps to restore normal testosterone levels, which improves the sexual drive, enhance better erectile function, and orgasmic response.
   
• Additionally, healthcare policies and regulatory frameworks that support TRT availability have boosted market access and encouraged research and development initiatives.
   
• For instance, in August 2022, the Food and Drug Administration (FDA) had approved Kyzatrex (testosterone undecanoate) for testosterone replacement therapy in adult males with conditions related to a deficiency or absence of endogenous testosterone. This regulatory support has strengthened the foundation for continued therapeutic advancement in testosterone therapy.
   
• Further, testosterone influenced in fat metabolism and helps in fat redistribution. Thus, low testosterone levels are linked to increased visceral fat accumulation. So, testosterone replacement therapy has shown positive result in minimizing body fat percentage and also improves metabolic function, which helps in enhancing insulin sensitivity.
   
• Moreover, research into testosterone's effects on various health conditions and its therapeutic applications has enabled the development of improved treatments such as testosterone replacement therapy. These research developments have contributed to more targeted and effective treatment approaches for patients with testosterone deficiency.
   

Based on route of administration, the male hypogonadism market is segmented into injectable, topical, and oral. The injectable segment accounted for a revenue share of 55.3% and with revenue of USD 2.2 billion in 2024.
 

• Injectable testosterone ensures stable hormone levels, minimizing mood swings, fatigue and libido fluctuations compared to the oral or topical form.
   
• Injectable therapies such as testosterone enanthate and testosterone cypionate has shown effectiveness in restoring testosterone levels. Their reliability and proven results ensure their steady use among patients and healthcare providers.
   
• Additionally, injectable testosterone allows for precise dosage adjustments, which helps physicians to treat patients according to their specific needs. This flexibility helps in optimizing testosterone levels, while it reduces the associated side effects.
   
• Further, research into testosterone therapy benefits and new injectable formulations which helps to drives the market expansion. For instance, in October 2023, Aurobindo Pharma received approval from the US Food and Drug Administration (FDA) to manufacture and market Testosterone Cypionate injection in concentrations of 100 mg/mL and 200 mg/mL in multi-dose vials, as well as 200 mg/mL in single-dose vials.
   
• Thus, this product was indicated for replacement therapy in males with primary hypogonadism and hypogonadotropic hypogonadism. Such approvals are expected to significantly boost the growth of the injectable segment over the forecast period.
   

Based on application, the male hypogonadism market is segmented into Kallmann syndrome, Klinefelter syndrome, pituitary disorders, and other applications. The Klinefelter syndrome segment dominated the market with the largest revenue of USD 1.5 billion in 2024.
 

• Klinefelter syndrome is a genetic condition in which males have an extra X chromosome, which leads to testosterone deficiency and symptoms associated with it.
   
• For instance, according to the March 2024 article of National Organization for Rare Disorders, Klinefelter syndrome, specifically the 47,XXY variant, is the most common chromosomal abnormality in males, occurring in approximately 1 out of every 500 males, indicating an increasing demand for treatment options.
   
• In addition, increased awareness of Klinefelter syndrome and its link to hypogonadism has led to higher diagnosis rates, as healthcare providers are now better able to recognize symptoms and implement appropriate treatments.
   
• Moreover, innovations in testosterone replacement therapy (TRT) formulations and delivery methods have increased treatment options for patients with Klinefelter syndrome. These advanced treatments provides improved safety profiles and effectiveness, accelerating greater adoption of therapy among affected individuals.
   

The North America male hypogonadism market is accounted for 1.8 billion revenues in 2024 forecasted to reach USD 3.1 billion by 2034. The U.S. dominated the North America market with the largest revenue of USD 1.6 billion in 2023.
 

• This growth is largely attributed due to the rising aging U.S. population, particularly men over 40 years, experiences significant hormonal changes.
   
• For instance, according to the U.S. Census Bureau, the number of individuals in the U.S. aged 65 and older is projected to reach 77 million by 2034, representing a substantial demographic shift. This demographic trend suggests a sustained increase in hypogonadism diagnosis and treatment requirements.
   
• In addition to this, the U.S. Food and Drug Administration (FDA) has implemented rigorous standards for treatment options such as testosterone replacement therapy or other pharmaceuticals solutions, driving the development of high-quality products with enhanced safety, efficacy, and stability to meet the growing demand for effective treatments.
   

Europe: The male hypogonadism market in UK is expected to experience significant and promising growth from 2025 to 2034.
 

• The improved access to healthcare services, including primary care and endocrinology, enables better diagnosis and management of male hypogonadism. The availability of testosterone replacement therapy through the National Health Service (NHS) has increased patient access to treatment.
   
• Additionally, collaborations between pharmaceutical companies in the region have increased the demand for male hypogonadism treatments. For instance, in September 2024, Marius Pharmaceuticals announced a partnership with Numan, a prominent UK-based digital health platform, to integrate KYZATREX (testosterone undecanoate) CIII capsules into Numan's product portfolio. These partnership have enhanced treatment accessibility and improved patient outcomes in the region.
   

Asia Pacific: Japan male hypogonadism market is anticipated to witness lucrative growth between 2025 – 2034.
 

• Japan has a massive aging society; according to Statista, as of November 2023, around 36.35 million people in Japan were estimated to be over 65 years of age.
   
• Therefore, it is expected that an aging society will heavily affect the disease burden in Japan in near future and correlates with increased cases of late-onset hypogonadism, generating higher demand for diagnostic and therapeutic solutions.
   
• Additionally, the Japanese pharmaceutical market has adopted advanced testosterone replacement therapy (TRT) options, including formulations that offer heightened safety and patient compliance. These advancements have gained acceptance among patients and healthcare providers, contributing to market expansion.
   

Middle East and Africa: The male hypogonadism market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• Saudi Arabia is also experiencing a shift in population demographics. For instance, the number of people aged 60+ is expected to increase five times from 2 million (5.9% of the total population) in 2020, reaching 10.5 million by 2050.
   
• Thus, this demographic trend suggests a sustained increase in hypogonadism diagnosis and treatment requirements.
   
• Additionally, the Saudi Vision 2030 initiative highlights healthcare infrastructure development, which improves access to specialized endocrine care. This includes increased funding and resources for diagnosing and treating conditions such as hypogonadism.
   

Male Hypogonadism Market Share

The top 4 players of the market account for approximately 45% of the market share which includes companies such as AbbVie, Eli Lilly and Company, Pfizer, Sanofi, among others. With every firm introducing new drugs and using advanced treatments, modernization is extremely important. Moreover, strategic partnerships with pharmaceutical companies, research institutes, and government agencies play a primary role in advancing the development of drugs and getting the necessary permits.
 

The development of public awareness about hypogonadism and its health impact through the social media platform, will encourage more individuals to seek the treatment, enabling market players to strengthen their position in this growing sector.
 

Male Hypogonadism Market Companies

Some of the eminent market participants operating in the male hypogonadism industry include:

• AbbVie
• Antares Pharma
• Bayer
• Eli Lilly and Company
• Endo Pharmaceuticals
• Simple Pharma
• Pfizer
• Sanofi
• Teva Pharmaceutical Industries
• Viatris
   
• Eli Lilly is leading in the development of advanced therapies for male hypogonadism, including novel testosterone formulations, thereby strengthening the company’s product portfolio.
   
• Pfizer has strong global workforce of approximately 88,000 employees, which enables the company to drive innovation, and deliver high-quality solutions.
   
• Sanofi has strong geographical presence which enables it to enhance its market reach. Sanofi operates in more than 90 countries thus comprising of a robust distribution network.
   

Male Hypogonadism Industry News:

• In March 2022, Antares Pharma announced that U.S. Food and Drug Administration approved TLANDO (testosterone undecanoate), an oral treatment for testosterone replacement therapy (TRT). This approval marked a significant milestone for the company, expanding its product portfolio and reinforcing its position in the TRT market.
   
• In February 2021, Simple Pharma acquired Testavan (transdermal testosterone gel 2%) for male hypogonadism and Vitaros (alprostadil cream) for Erectile Dysfunction (ED) from Ferring Pharmaceuticals, strengthening its portfolio in male health therapies.
   

The male hypogonadism market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment Type

• Testosterone replacement therapy
• Gonadotropin therapy

Market, By Route of Administration

• Injectable
• Topical
• Oral

Market, By Application

• Kallmann syndrome
• Klinefelter syndrome
• Pituitary disorders
• Other applications

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE